Effects of ageing, prolonged estrogen deficiency and zoledronate on bone tissue mineral distribution

Journal of the Mechanical Behavior of Biomedical Materials

Volumn 29, Issue , 2014, Pages 161-170

  Brennan, M A ^a,b   Gleeson, J P ^c,d   O'Brien, F J ^c,d   McNamara, L M ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

BMDD; Heterogeneity; Mineralization; Osteoporosis; Trabeculae; Zoledronic acid

Indexed keywords

DISEASES; FRACTURE; MINERALOGY; MINERALS; TISSUE;

BMDD; HETEROGENEITY; MINERALIZATION; OSTEOPOROSIS; TRABECULAE; ZOLEDRONIC ACID;

BONE;

ZOLEDRONIC ACID;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MINERAL; BONE MINERALIZATION; CONTROLLED STUDY; ESTROGEN DEFICIENCY; FEMUR HEAD; GREATER TROCHANTER; LESSER TROCHANTER; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL;

BMDD; HETEROGENEITY; MINERALIZATION; OSTEOPOROSIS; TRABECULAE; ZOLEDRONIC ACID;

AGING; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIFICATION, PHYSIOLOGIC; DIPHOSPHONATES; ESTROGENS; FEMUR; IMIDAZOLES; SHEEP; TIME FACTORS;

EID: 84884963680     PISSN: 17516161     EISSN: 18780180     Source Type: Journal    
DOI: 10.1016/j.jmbbm.2013.08.029     Document Type: Article

References (53)

1. Baldock, P.A., Morris, H.A., Need, A.G., Moore, R.J., Durbridge, T.C., 1998. Variation in the short-term changes in bone cell activity in three regions of the distal femur immediately following ovariectomy. Journal of Bone and Mineral Research 13, 1451-1457.
2. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., Opas E.E., Seedor J.G., Klein H., Frankenfield D., et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. Journal of Clinical Investigation 1993, 92:2577-2586.
3. Binkley N., Kimmel D., Bruner J., Haffa A., Davidowitz B., Meng C., Schaffer V., Green J. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. Journal of Bone and Mineral Research 1998, 13:1775-1782.
4. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Ensrud K.E. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
5. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T.F., Sellmeyer D., Eriksen E.F., Cummings S.R. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine 2007, 356:1809-1822.
6. Bloebaum R.D., Lundeen G.A., Shea J.E., Whitaker E.L. Age-related mineralization heterogeneity changes in trabecular bone of the proximal femur. Anatomical Record A, Discoveries in Molecular, Cellular, and Evolutionary Biology 2004, 281:1296-1302.
7. Bonfield W., Clark E.A. Elastic deformation of compact bone. Journal of Materials Science 1973, 8:1590-1594.
8. Boyde A., Compston J.E., Reeve J., Bell K.L., Noble B.S., Jones S.J., Loveridge N. Effect of estrogen suppression on the mineralization density of iliac crest biopsies in young women as assessed by backscattered electron imaging. Bone 1998, 22:241-250.
9. Brennan M.A., Gleeson J.P., Browne M., O'Brien F.J., Thurner P.J., McNamara L.M. Site specific increase in heterogeneity of trabecular bone tissue mineral during oestrogen deficiency. Journal of European Cells and MaterialsEuropean Cells and Materials 2011, 21:396-406.
10. Brennan O., Kennedy O.D., Lee T.C., Rackard S.M., O'Brien F.J. Biomechanical properties across trabeculae from the proximal femur of normal and ovariectomised sheep. Journal of Biomechanics 2009, 42:498-503.
11. Busse B., Djonic D., Milovanovic P., Hahn M., Püschel K., Ritchie R.O., Djuric M., Amling M. Decrease in the osteocyte lacunar density accompanied by hypermineralized lacunar occlusion reveals failure and delay of remodeling in aged human bone. Aging Cell 2010, 9:1065-1075.
12. Busse B., Hahn M., Soltau M., Zustin J., Püschel K., Duda G.N., Amling M. Increased calcium content and inhomogeneity of mineralization render bone toughness in osteoporosis: mineralization, morphology and biomechanics of human single trabeculae. Bone 2009, 45:1034-1043.
13. Carpentier V.T., Wong J., Yeap Y., Gan C., Sutton-Smith P., Badiei A., Fazzalari N.L., Kuliwaba J.S. Increased proportion of hypermineralized osteocyte lacunae in osteoporotic and osteoarthritic human trabecular bone: Implications for bone remodeling. Bone 2012, 50:688-694.
14. Ciarelli T.E., Fyhrie D.P., Parfitt A.M. Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone 2003, 32(3):311-315.
15. Cummings S.R., Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761-1767.
16. Currey J.D. The mechanical consequences of variation in the mineral content of bone. Journal of Biomechanics 1969, 2:1-11.
17. Currey J.D. Effects of differences in mineralization on the mechanical properties of bone. Philosophical Transactions of the Royal Society B: Biological Sciences 1984, 304:509-518.
18. Currey J.D., Brear K., Zioupos P. The effects of ageing and changes in mineral content in degrading the toughness of human femora. Journal of Biomechanics 1996, 29:257-260.
19. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J., Glüer C.C., Krueger K., Cohen F.J., Eckert S., Ensrud K.E., Avioli L.V., Lips P., Cummings S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637-645.
20. Follet H., Boivin G., Rumelhart C., Meunier P.J. The degree of mineralization is a determinant of bone strength: a study on human calcanei. Bone 2004, 34:783-789.
21. Gadeleta S.J., Boskey A.L., Paschalis E., Carlson C., Menschik F., Baldini T., Peterson M., Rimnac C.M. A physical, chemical, and mechanical study of lumbar vertebrae from normal, ovariectomized, and nandrolone decanoate-treated cynomolgus monkeys (Macaca fascicularis). Bone 2000, 27:541-550.
22. Gamsjaeger S., Buchinger B., Zwettler E., Recker R., Black D., Gasser J.A., Eriksen E.F., Klaushofer K., Paschalis E.P. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. Journal of Bone and Mineral Research 2011, 26:12-18.
23. Glatt M. The bisphosphonate zoledronate prevents vertebral bone loss in mature estrogen-deficient rats as assessed by micro-computed tomography. European Cells and Materials 2001, 1:18-26.
24. Grynpas M.D., Huckell C.B., Reichs K.J., Derousseau C.J., Greenwood C., Kessler M.J. Effect of age and osteoarthritis on bone mineral in rhesus monkey vertebrae. Journal of Bone and Mineral Research 1993, 8:909-917.
25. Hernandez C.J. How can bone turnover modify bone strength independent of bone mass?. Bone 2008, 42:1014-1020.
26. Hernandez C.J., Beaupre G.S., Keller T.S., Carter D.R. The influence of bone volume fraction and ash fraction on bone strength and modulus. Bone 2001, 29:74-78.
27. Huang, C., Ogawa, R., 2011. Mechanotransduction in bone repair and regeneration. FASEB J 24, 3625-32.
28. Jaasma M.J., Bayraktar H.H., Niebur G.L., Keaveny T.M. Biomechanical effects of intraspecimen variations in tissue modulus for trabecular bone. Journal of Biomechanics 2002, 35:237-246.
29. Kingsmill V.J., Boyde A. Mineralisation density of human mandibular bone: quantitative backscattered electron image analysis. Journal of Anatomy 1998, 192(Pt 2):245-256.
30. Leal T., Tevaarwerk A., Love R., Stewart J., Binkley N., Eickhoff J., Parrot B., Mulkerin D. Randomized trial of adjuvant Zoledronic acid in postmenopausal women with high-risk breast cancer. Clinical Breast Cancer 2010, 10:471-476.
31. Liberman U.A., Weiss S.R., Bröll J., Minne H.W., Quan H., Bell N.H., Rodriguez-Portales J., Downs R.W., Dequeker J., Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. New England Journal of Medicine 1995, 333:1437-1443.
32. Loveridge N., Power J., Reeve J., Boyde A. Bone mineralization density and femoral neck fragility. Bone 2004, 35:929-941.
33. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., Adami S., Fogelman I., Diamond T., Eastell R., Meunier P.J., Wasnich R.D., Greenwald M., Kaufman J.-M., Chesnut C.H., Reginster J.-Y. Effect of risedronate on the risk of hip fracture in elderly women. New England Journal of Medicine 2001, 344:333-340.
34. McNamara L.M., Ederveen A.G., Lyons C.G., Price C., Schaffler M.B., Weinans H., Prendergast P.J. Strength of cancellous bone trabecular tissue from normal, ovariectomized and drug-treated rats over the course of ageing. Bone 2006, 39:392-400.
35. Mulvihill B.M., McNamara L.M., Prendergast P.J. Loss of trabeculae by mechano-biological means may explain rapid bone loss in osteoporosis. Journal of the Royal Society Interface 2008, 5:1243-1253.
36. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., Widmer A., Devogelaer J.P., Kaufman J.M., Jaeger P., Body J.J., Brandi M.L., Broell J., Di Micco R., Genazzani A.R., Felsenberg D., Happ J., Hooper M.J., Ittner J., Leb G., Mallmin H., Murray T., Ortolani S., Rubinacci A., Saaf M., Samsioe G., Verbruggen L., Meunier P.J. Intravenous Zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine 2002, 346:653-661.
37. Renders G.A.P., Mulder L., Langenbach G.E.J., Van Ruijven L.J., Van Eijden T.M.G.J. Biomechanical effect of mineral heterogeneity in trabecular bone. Journal of Biomechanics 2008, 41:2793-2798.
38. Riggs B.L. Endocrine causes of age-related bone loss and osteoporosis. Novartis Foundation Symposium 2002, 242:247-259. (discussion 260-4).
39. Riggs B.L., Khosla S., Melton L.J. Sex steroids and the construction and conservation of the adult skeleton. Endocrine Reviews 2002, 23:279-302.
40. Rizzoli R. Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis. Therapeutic Advances in Musculoskeletal Disease 2009, 2:3-16.
41. Rodan G.A., Reszka A.A. Bisphosphonate mechanism of action. Current Molecular Medicine 2002, 2:571-577.
42. Roelofs A.J., Coxon F.P., Ebetino F.H., Lundy M.W., Henneman Z.J., Nancollas G.H., Sun S., Blazewska K.M., Bala J.L.F., Kashemirov B.A., Khalid A.B., McKenna C.E., Rogers M.J. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. Journal of Bone and Mineral Research 2010, 25:606-616.
43. Roschger P., Fratzl P., Eschberger J., Klaushofer K. Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies - backscattered electron image grey - levels correlated to calcium Kα-line intensities. Bone 1998, 23:319-326.
44. Roschger P., Fratzl P., Klaushofer K., Rodan G. Mineralization of cancellous bone after alendronate and sodium fluoride treatment: a quantitative backscattered electron imaging study on minipig ribs. Bone 1997, 20:393-397.
45. Roschger P., Rinnerthaler S., Yates J., Rodan G.A., Fratzl P., Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001, 29:185-191.
46. Sarkar S., Mitlak B.H., Wong M., Stock J.L., Black D.M., Harper K.D. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. Journal of Bone and Mineral Research 2002, 17:1-10.
47. Smith S.Y., Recker R.R., Hannan M., Muller R., Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003, 32:45-55.
48. Sterck J.G., Klein-Nulend J., Lips P., Burger E.H. Response of normal and osteoporotic human bone cells to mechanical stress in vitro. American Journal of Physiology 1998, 274:E1113-E1120.
49. Vajda E.G., Bloebaum R.D. Age-related hypermineralization in the female proximal human femur. Anatomical Record 1999, 255:202-211.
50. Vajda E.G., Skedros J.G., Bloebaum R.D. Errors in quantitative backscattered electron analysis of bone standardized by energy-dispersive x-ray spectrometry. Scanning 1998, 20:527-535.
51. Van der Linden J.C., Birkenhager-Frenkel D.H., Verhaar J.A., Weinans H. Trabecular bone's mechanical properties are affected by its non-uniform mineral distribution. Journal of Biomechanics 2001, 34:1573-1580.
52. Vose G., Kubala A. Bone strength - its relationship to x-ray determined ash content. Human Biology 1959, 261-270.
53. Yao W., Cheng Z., Koester K.J., Ager J.W., Balooch M., Pham A., Chefo S., Busse C., Ritchie R.O., Lane N.E. The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength. Bone 2007, 41:804-812.